Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01373
|
|||||
| Drug Name |
Cephaloglycin
|
|||||
| Synonyms |
CEG; Cefaloglicina; Cefaloglycin; Cefaloglycine; Cefaloglycinum; Cephaloglycine; Kafocin; Kefglycin; Cephaloglycinanhdyous; Cephaloglycin anhydrous; Cephaoglycin acid; Lilly 39435; Cefaloglicina [INN-Spanish]; Cefaloglycin (JAN); Cefaloglycine [INN-French]; Cefaloglycinum [INN-Latin]; Cephaloglycin (anhydrous); D-Cephaloglycine; D-(-)-Cephaloglycin; (6R,7R)-3-(acetoxymethyl)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(acetyloxymethyl)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-((Acetyloxy)methyl)-7-((aminophenylacetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-acetoxymethyl-7beta-[(2R)-2-amino-2-phenylacetamido]-3,4-didehydrocepham-4-carboxylic acid; 7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate (ester); 7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)octane-2-carboxylic acid, acetate inner salt; 7-(2-D-alpha-Aminophenylacetamido)cephalosporanic acid; 7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup 3)-cephem-4-carboxylic acid; 7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup3)-cephem-4-carboxylic acid; 7-(D-alpha-Aminophenyl-acetamido)cephalosporanic acid
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Bacterial infections [ICD11:1A00-1H0Z] | Approved | [1] | |||
| Therapeutic Class |
Antibiotics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C18H19N3O6S
|
|||||
| Canonical SMILES |
CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=CC=C3)N)SC1)C(=O)O
|
|||||
| InChI |
InChI=1S/C18H19N3O6S/c1-9(22)27-7-11-8-28-17-13(16(24)21(17)14(11)18(25)26)20-15(23)12(19)10-5-3-2-4-6-10/h2-6,12-13,17H,7-8,19H2,1H3,(H,20,23)(H,25,26)/t12-,13-,17-/m1/s1
|
|||||
| InChIKey |
FUBBGQLTSCSAON-PBFPGSCMSA-N
|
|||||
| CAS Number |
CAS 3577-01-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 405.4 | Topological Polar Surface Area | 164 | ||
| Heavy Atom Count | 28 | Rotatable Bond Count | 7 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
-3
|
|||||
| PubChem CID | ||||||
| PubChem SID | ||||||
| ChEBI ID |
CHEBI:34613
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [2] | |
| References | ||||||
| 1 | Cephaloglycin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol. 2008 May;60(5):543-85. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.